This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (5)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Neurology  • Cerebrovascular Disease  • Stroke  • Cardiovascular Disease/ Myocardial Infarction  • Genetic Counseling/ Testing/ Therapy  • Genetics, Other  • Alert me on articles by topic

Christopher J. O’Donnell, MD, MPH

JAMA. 2005;293:2277-2279.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

With a nearly completed Human Genome Project,¹ it is hoped that the road from the complete genome sequence of 2.85 billion nucleotides containing up to 25 000 genes will lead to a promised land of new and better patient-tailored diagnostics and treatments. Some have even predicted the end of common complex diseases such as myocardial infarction (MI) as a major public health problem in the near future.² Risks for MI and stroke are conferred by established major modifiable risk factors, including hyperlipidemia and hypertension, as well as other factors, such as inflammation. Cardiovascular disease risks are also substantially increased in those with disease occurrence in twin siblings³ or parents.⁴ This suggests that genetic variation may lead to increased risk, although to date few genetic variants have emerged as strong candidates. The randomized trial described by Hakonarson et al⁵ in this issue of JAMA—suggesting that inhibition . . . [Full Text of this Article]

Author Affiliations: National Heart, Lung, and Blood Institute, Framingham Heart Study Cardiology Division, and Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston.

RELATED ARTICLE

Effects of a 5-Lipoxygenase–Activating Protein Inhibitor on Biomarkers Associated With Risk of Myocardial Infarction: A Randomized Trial
Hakon Hakonarson, Sverrir Thorvaldsson, Anna Helgadottir, Daniel Gudbjartsson, Florian Zink, Margret Andresdottir, Andrei Manolescu, David O. Arnar, Karl Andersen, Axel Sigurdsson, Gestur Thorgeirsson, Asgeir Jonsson, Uggi Agnarsson, Halldora Bjornsdottir, Gizur Gottskalksson, Atli Einarsson, Hrefna Gudmundsdottir, Asdis E. Adalsteinsdottir, Kolbeinn Gudmundsson, Kristleifur Kristjansson, Thordur Hardarson, Arni Kristinsson, Eric J. Topol, Jeffrey Gulcher, Augustine Kong, Mark Gurney, Gudmundur Thorgeirsson, and Kari Stefansson
JAMA. 2005;293(18):2245-2256.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Genetic Testing in Cardiovascular Disease
Robin et al.
J Am Coll Cardiol 2007;50:727-737.
ABSTRACT | FULL TEXT  

Particulate Levels Are Associated with Early Asthma Worsening in Children with Persistent Disease
Rabinovitch et al.
Am. J. Respir. Crit. Care Med. 2006;173:1098-1105.
ABSTRACT | FULL TEXT  

Can Gene Modulation Reduce Biomarkers of MI Risk?
Journal Watch Cardiology 2005;2005:2-2.
FULL TEXT